Literature DB >> 20067558

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia.

Claire M Lucas, Robert J Harris, Athina Giannoudis, Katy Knight, Sarah J Watmough, Richard E Clark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20067558     DOI： 10.1111/j.1365-2141.2009.08066.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  7 in total

1.  c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.

Authors:  Claire M Lucas; Robert J Harris; Athina Giannoudis; Richard E Clark
Journal:  Haematologica       Date:  2015-02-06       Impact factor: 9.941

2.  Enzymatic-based cytometry, a sensitive single-cell cytometric method to assess BCR-ABL1 activity in CML.

Authors:  Jinzhu Yu; Ki Oh; Sitapriya Moorthi; Ling Li; Helmut H Strey; Michael Schuster; Chiara Luberto; Phenix-Lan Quan; Eric Brouzes
Journal:  Lab Chip       Date:  2020-03-03       Impact factor: 6.799

3.  Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity.

Authors:  Christian Boni; Massimiliano Bonifacio; Marzia Vezzalini; Luigi Scaffidi; Luisa Tomasello; Laurie L Parker; Diego Boscarino; Dino Paladin; Mauro Krampera; Claudio Sorio
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

4.  Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.

Authors:  C M Lucas; R J Harris; A K Holcroft; L J Scott; N Carmell; E McDonald; F Polydoros; R E Clark
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia.

Authors:  Yoji Ishida; Kazunori Murai; Kohei Yamaguchi; Takuto Miyagishima; Motohiro Shindo; Kazuei Ogawa; Takahiro Nagashima; Shinji Sato; Reiko Watanabe; Satoshi Yamamoto; Takayuki Hirose; Souich Saitou; Masakatsu Yonezumi; Takeshi Kondo; Yuichi Kato; Noboru Mochizuki; Keiko Ohno; Satoshi Kishino; Kohmei Kubo; Tatsuo Oyake; Shigeki Ito
Journal:  Eur J Clin Pharmacol       Date:  2015-10-27       Impact factor: 2.953

6.  Domain organization differences explain Bcr-Abl's preference for CrkL over CrkII.

Authors:  Wojciech Jankowski; Tamjeed Saleh; Ming-Tao Pai; Ganapathy Sriram; Raymond B Birge; Charalampos G Kalodimos
Journal:  Nat Chem Biol       Date:  2012-05-13       Impact factor: 15.040

Review 7.  Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia.

Authors:  Christian Boni; Claudio Sorio
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.